Savient Pharmaceuticals
Study to Assess Pegloticase (KRYSTEXXAยฎ) in Patients on Hemodialysis
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT01739660
- Locations
- ๐บ๐ธ
Davita Clinical Research, Minneapolis, Minnesota, United States
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 151
- Registration Number
- NCT01356498
- Locations
- ๐บ๐ธ
Pacific Arthritis Center Medical Group, Santa Maria, California, United States
๐บ๐ธVeterans Affairs Medical Center, Washington, District of Columbia, United States
๐บ๐ธGraves Gilbert Clinic, Bowling Green, Kentucky, United States
Re-exposure Study of Pegloticase Intravenous (i.v.) in Symptomatic Gout Patients
- Conditions
- Interventions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 7
- Registration Number
- NCT00675103
- Locations
- ๐บ๐ธ
University of Chicago- Dept. Biological Services, Chicago, Illinois, United States
๐บ๐ธThe Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2011-02-28
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT00325195
- Locations
- ๐บ๐ธ
Arthritis & Rheumatic Disease Specialties, Aventura, Florida, United States
๐บ๐ธThe University of Chicago, Chicago, Illinois, United States
๐บ๐ธPhysicians East, P.A., Greenville, North Carolina, United States
Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients
- Conditions
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2006-02-03
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 350
- Registration Number
- NCT00286377
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
- Conditions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2013-06-03
- Lead Sponsor
- Savient Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT00080210
- Locations
- ๐บ๐ธ
University of Chicago Dept of Medicine, Chicago, Illinois, United States
๐บ๐ธNorth Shore University Hospital Division of Rheumatology, Manhasset, New York, United States
๐บ๐ธOregon Health & Science University Arthritis & Rheumatic Diseases, Portland, Oregon, United States